HEMLIBRA®

(Emicizumab kxwh)

Documentation

Patented
Approved 2017
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: ADC ADCC
Target: FactorIXa FactorX
Indication Category: Hemophilia

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA